Thola Biotechnologies, an African based biotechnology company that was formed to provide solutions to the medical services sector, born out of the Coronavirus pandemic.
Antigenic drift: the accumulations of mutations. SARS-CoV-2 501Y.V2 mutation demonstrate a mutation on the spike protein that allows for greater binding affinity to the ACE2 receptor, allowing for increased transmissibility.
Mutations in S gene, coding for the spike protein could cause S gene fall out in testing implications and reduce testing accuracy.
PCR testing directly tests for the presence of virus and common PCR assays like Thermofisher detects 3 targets → S, ORF1a and E gene have shown S gene fall outs in UK (N439k) and South African variant (501Y.V2) .
Testing therefore in South Africa is shifting away from Spiking protein or S gene detection and preferring Nucleocapsid or N gene targets.
Testing for the presence of the virus Gold standard for diagnosing COVID-19
CHALLENGES
BENEFITS
Test is performed from a nasopharyngeal or oropharyngeal swaps
Testing for the presence of the virus Used in screening for COVID-19
CHALLENGES
BENEFITS
Test is performed from a nasopharyngeal or oropharyngeal swaps
Testing the response of the body when it was exposed to COVID-19
Should be used after COVID-19 infection or vaccination to determine if the body produced antibodies/immune response against the virus.
This test should not be used to diagnose COVID-19
CHALLENGES
BENEFITS
Test is performed from whole blood, blood serum or blood plasma. A skilled individual will have to draw blood to perform this test
Please keep in contact with your health care provider telephonically to monitor your progress.
Your healthcare provider will assess you in terms of your current coronavirus illness and your other risk factors for more severe illness (i.e. older age, serious underlying medical conditions such as diabetes mellitus, heart disease, lung disease and immunosuppression, etc.).
Smoking any kind of tobacco reduces lung capacity and increases the risk of many respiratory infections and can increase the severity of respiratory diseases. COVID-19 is an infectious disease that primarily attacks the lungs. Smoking impairs lung function making it harder for the body to fight off coronaviruses and other respiratory diseases. Available research suggests that smokers are at higher risk of developing severe COVID-19 outcomes and death.
While you are recovering at home, your doctor or a public health official will check in with you about how you’re feeling. You must tell them if you notice new or worsening symptoms, so they can make the best decision about how to manage your illness. If you become more unwell, they may decide you need to be moved to hospital.
If you notice new or worsening symptoms that are concerning you at any time, contact your doctor, ambulance or call 0800 029 999.
The ill person should stay in a separate room. If this is not possible, then keep at least a 1-metre distance from them. The sick person and anyone else in the same room should wear a medical mask.
Provide good ventilation in the room of the ill person and shared spaces, and open windows if possible and safe to do so.
You should always call an ambulance if:
In a medical emergency in South Africa, call 10111 or 10177.
We will apply to the Ministry of Health Italia for approval of HIPRO Rapid SARS-CoV-2 Antigen test kit to be distributed in Italia.
This product is cost-effective and a rapid point-of-care solution. With individually packaged buffer solutions for every test, minimizing possible buffer contamination, and the specimen used is saliva this product a valuable prospect for self testing solutions or non professional.
This saliva based antigen tests from HIPRO detects antigen based on the viral nucleocapsid protein coded by the very stable N gene and will be useful to test children due to the non-invasive sample collection technique.
Sensitivity (Positive incidence rate): 70%
Specificity (Negative incidence rate): 85,5%
We offer a complete turnkey service including assessment, design, supply, financing, implementation, asset management and ongoing maintenance of group specific projects in the public and private sector, providing ongoing impartial advice to key clients and active participation in each of our key focus areas. Together with our partners, we have completed some leading commercial projects across Africa in excess of $200 million and have developed various projects in excess of $1 billion.
Learn more about the types of test kits that we have avaliable
Thola Biotechnologies is a subsidiary of Elu Healthcare Holdings, an African based biotechnology company that was formed to provide solutions to the medical services sector, born out of the Coronavirus pandemic.
Thola Biotechnologies © 2021 | Website Design by Versys Media